Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma

Andrew C. Birkeland, Megan Yanik, Brittny N. Tillman, Megan V. Scott, Susan K. Foltin, Jacqueline E. Mann, Nicole L. Michmerhuizen, Megan L. Ludwig, Morgan M. Sandelski, Christine M. Komarck, Thomas E. Carey, Mark E.P. Prince, Carol R. Bradford, Jonathan B. McHugh, Matthew E. Spector, J. Chad Brenner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Importance: ERBB2 (formerly HER2) is an important drug target in breast cancer, where anti-ERBB2 therapy has been shown to lead to improvements in disease recurrence and overall survival. ERBB2 status in head and neck squamous cell carcinoma (HNSCC) has not been well studied. Identification of ERBB2-positive tumors and characterization of response to ERBB2 therapy could lead to targeted treatment options in HNSCC. Objective: To identify ERBB2 aberrations in HNSCCs and investigate the potential for ERBB2-targeted therapy in HNSCCs. Design, Setting, and Participants: A retrospective case series of patients with laryngeal (42 tumor specimens) and oral cavity (94 tumor specimens) SCC enrolled in the University of Michigan Head and Neck Specialized Program of Research Excellence was conducted. Publicly available sequencing data (The Cancer Genome Atlas), as well as data from other studies, were reviewed to identify additional mutations and overexpression in ERBB2 in HNSCC. Established HNSCC cell lines were used for follow-up in vitro analysis. The study was conducted from October 1, 2014, to August 30, 2015. Interventions: With the use of targeted, amplicon-based sequencing with the Oncomine Cancer Panel, the copy number and mutation status of commonly altered genes in HNSCCs were assessed. Immunohistochemical staining was performed on tissue microarrays of HNSCCs to assess the expression of ERBB2. Western blotting for HNSCC cell line ERBB2 expression and cell survival assays after treatment with ERBB2 inhibitors were performed. Main Outcomes and Measures: The prevalence of ERBB2 genetic aberrations and ERBB2 overexpression in laryngeal and oral cavity SCCs, prevalence of ERBB2 aberrations in HNSCC in The Cancer Genome Atlas, ERBB2 protein expression in HNSCC cell lines, and response of HNSCC cell lines to targeted ERBB2 inhibitors. Results: Of the 42 laryngeal SCC samples screened by targeted sequencing, 4 (10%) were positive for ERBB2 amplification. Two of these samples showed ERBB2 overexpression on immunohistochemistry. Two of the 94 oral cavity SCC samples (2%) were positive for ERBB2 on immunohistochemistry. Analysis of 288 patients from publicly available HNSCC sequencing data revealed 9 amplifications (3%) in ERBB2. Protein expression was variable across HNSCC cell lines, and a subset of these cell lines showed responsiveness to anti-ERBB2 therapy. Conclusions and Relevance: ERBB2 aberrations were identified in a subset of HNSCCs. These tumors may be responsive to targeted therapy against ERBB2. Screening for ERBB2 aberrations and applying targeted therapy in ERBB2-positive patients may be useful in personalized therapy trials, particularly in patients who are refractory to current treatment paradigms.

Original languageEnglish (US)
Pages (from-to)559-567
Number of pages9
JournalJAMA Otolaryngology - Head and Neck Surgery
Volume142
Issue number6
DOIs
StatePublished - Jun 2016
Externally publishedYes

Fingerprint

Cell Line
Neoplasms
Mouth
Therapeutics
Atlases
Immunohistochemistry
Carcinoma, squamous cell of head and neck
Genome
Mutation
Cell Survival
Proteins
Neck
Western Blotting
Head
Outcome Assessment (Health Care)
Staining and Labeling
Breast Neoplasms
Recurrence
Survival
Research

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology

Cite this

Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma. / Birkeland, Andrew C.; Yanik, Megan; Tillman, Brittny N.; Scott, Megan V.; Foltin, Susan K.; Mann, Jacqueline E.; Michmerhuizen, Nicole L.; Ludwig, Megan L.; Sandelski, Morgan M.; Komarck, Christine M.; Carey, Thomas E.; Prince, Mark E.P.; Bradford, Carol R.; McHugh, Jonathan B.; Spector, Matthew E.; Brenner, J. Chad.

In: JAMA Otolaryngology - Head and Neck Surgery, Vol. 142, No. 6, 06.2016, p. 559-567.

Research output: Contribution to journalArticle

Birkeland, AC, Yanik, M, Tillman, BN, Scott, MV, Foltin, SK, Mann, JE, Michmerhuizen, NL, Ludwig, ML, Sandelski, MM, Komarck, CM, Carey, TE, Prince, MEP, Bradford, CR, McHugh, JB, Spector, ME & Brenner, JC 2016, 'Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma', JAMA Otolaryngology - Head and Neck Surgery, vol. 142, no. 6, pp. 559-567. https://doi.org/10.1001/jamaoto.2016.0335
Birkeland, Andrew C. ; Yanik, Megan ; Tillman, Brittny N. ; Scott, Megan V. ; Foltin, Susan K. ; Mann, Jacqueline E. ; Michmerhuizen, Nicole L. ; Ludwig, Megan L. ; Sandelski, Morgan M. ; Komarck, Christine M. ; Carey, Thomas E. ; Prince, Mark E.P. ; Bradford, Carol R. ; McHugh, Jonathan B. ; Spector, Matthew E. ; Brenner, J. Chad. / Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma. In: JAMA Otolaryngology - Head and Neck Surgery. 2016 ; Vol. 142, No. 6. pp. 559-567.
@article{cb66ddd125ea45afbd6cd4d0b3d0c87d,
title = "Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma",
abstract = "Importance: ERBB2 (formerly HER2) is an important drug target in breast cancer, where anti-ERBB2 therapy has been shown to lead to improvements in disease recurrence and overall survival. ERBB2 status in head and neck squamous cell carcinoma (HNSCC) has not been well studied. Identification of ERBB2-positive tumors and characterization of response to ERBB2 therapy could lead to targeted treatment options in HNSCC. Objective: To identify ERBB2 aberrations in HNSCCs and investigate the potential for ERBB2-targeted therapy in HNSCCs. Design, Setting, and Participants: A retrospective case series of patients with laryngeal (42 tumor specimens) and oral cavity (94 tumor specimens) SCC enrolled in the University of Michigan Head and Neck Specialized Program of Research Excellence was conducted. Publicly available sequencing data (The Cancer Genome Atlas), as well as data from other studies, were reviewed to identify additional mutations and overexpression in ERBB2 in HNSCC. Established HNSCC cell lines were used for follow-up in vitro analysis. The study was conducted from October 1, 2014, to August 30, 2015. Interventions: With the use of targeted, amplicon-based sequencing with the Oncomine Cancer Panel, the copy number and mutation status of commonly altered genes in HNSCCs were assessed. Immunohistochemical staining was performed on tissue microarrays of HNSCCs to assess the expression of ERBB2. Western blotting for HNSCC cell line ERBB2 expression and cell survival assays after treatment with ERBB2 inhibitors were performed. Main Outcomes and Measures: The prevalence of ERBB2 genetic aberrations and ERBB2 overexpression in laryngeal and oral cavity SCCs, prevalence of ERBB2 aberrations in HNSCC in The Cancer Genome Atlas, ERBB2 protein expression in HNSCC cell lines, and response of HNSCC cell lines to targeted ERBB2 inhibitors. Results: Of the 42 laryngeal SCC samples screened by targeted sequencing, 4 (10{\%}) were positive for ERBB2 amplification. Two of these samples showed ERBB2 overexpression on immunohistochemistry. Two of the 94 oral cavity SCC samples (2{\%}) were positive for ERBB2 on immunohistochemistry. Analysis of 288 patients from publicly available HNSCC sequencing data revealed 9 amplifications (3{\%}) in ERBB2. Protein expression was variable across HNSCC cell lines, and a subset of these cell lines showed responsiveness to anti-ERBB2 therapy. Conclusions and Relevance: ERBB2 aberrations were identified in a subset of HNSCCs. These tumors may be responsive to targeted therapy against ERBB2. Screening for ERBB2 aberrations and applying targeted therapy in ERBB2-positive patients may be useful in personalized therapy trials, particularly in patients who are refractory to current treatment paradigms.",
author = "Birkeland, {Andrew C.} and Megan Yanik and Tillman, {Brittny N.} and Scott, {Megan V.} and Foltin, {Susan K.} and Mann, {Jacqueline E.} and Michmerhuizen, {Nicole L.} and Ludwig, {Megan L.} and Sandelski, {Morgan M.} and Komarck, {Christine M.} and Carey, {Thomas E.} and Prince, {Mark E.P.} and Bradford, {Carol R.} and McHugh, {Jonathan B.} and Spector, {Matthew E.} and Brenner, {J. Chad}",
year = "2016",
month = "6",
doi = "10.1001/jamaoto.2016.0335",
language = "English (US)",
volume = "142",
pages = "559--567",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Identification of targetable ERBB2 aberrations in head and neck squamous cell carcinoma

AU - Birkeland, Andrew C.

AU - Yanik, Megan

AU - Tillman, Brittny N.

AU - Scott, Megan V.

AU - Foltin, Susan K.

AU - Mann, Jacqueline E.

AU - Michmerhuizen, Nicole L.

AU - Ludwig, Megan L.

AU - Sandelski, Morgan M.

AU - Komarck, Christine M.

AU - Carey, Thomas E.

AU - Prince, Mark E.P.

AU - Bradford, Carol R.

AU - McHugh, Jonathan B.

AU - Spector, Matthew E.

AU - Brenner, J. Chad

PY - 2016/6

Y1 - 2016/6

N2 - Importance: ERBB2 (formerly HER2) is an important drug target in breast cancer, where anti-ERBB2 therapy has been shown to lead to improvements in disease recurrence and overall survival. ERBB2 status in head and neck squamous cell carcinoma (HNSCC) has not been well studied. Identification of ERBB2-positive tumors and characterization of response to ERBB2 therapy could lead to targeted treatment options in HNSCC. Objective: To identify ERBB2 aberrations in HNSCCs and investigate the potential for ERBB2-targeted therapy in HNSCCs. Design, Setting, and Participants: A retrospective case series of patients with laryngeal (42 tumor specimens) and oral cavity (94 tumor specimens) SCC enrolled in the University of Michigan Head and Neck Specialized Program of Research Excellence was conducted. Publicly available sequencing data (The Cancer Genome Atlas), as well as data from other studies, were reviewed to identify additional mutations and overexpression in ERBB2 in HNSCC. Established HNSCC cell lines were used for follow-up in vitro analysis. The study was conducted from October 1, 2014, to August 30, 2015. Interventions: With the use of targeted, amplicon-based sequencing with the Oncomine Cancer Panel, the copy number and mutation status of commonly altered genes in HNSCCs were assessed. Immunohistochemical staining was performed on tissue microarrays of HNSCCs to assess the expression of ERBB2. Western blotting for HNSCC cell line ERBB2 expression and cell survival assays after treatment with ERBB2 inhibitors were performed. Main Outcomes and Measures: The prevalence of ERBB2 genetic aberrations and ERBB2 overexpression in laryngeal and oral cavity SCCs, prevalence of ERBB2 aberrations in HNSCC in The Cancer Genome Atlas, ERBB2 protein expression in HNSCC cell lines, and response of HNSCC cell lines to targeted ERBB2 inhibitors. Results: Of the 42 laryngeal SCC samples screened by targeted sequencing, 4 (10%) were positive for ERBB2 amplification. Two of these samples showed ERBB2 overexpression on immunohistochemistry. Two of the 94 oral cavity SCC samples (2%) were positive for ERBB2 on immunohistochemistry. Analysis of 288 patients from publicly available HNSCC sequencing data revealed 9 amplifications (3%) in ERBB2. Protein expression was variable across HNSCC cell lines, and a subset of these cell lines showed responsiveness to anti-ERBB2 therapy. Conclusions and Relevance: ERBB2 aberrations were identified in a subset of HNSCCs. These tumors may be responsive to targeted therapy against ERBB2. Screening for ERBB2 aberrations and applying targeted therapy in ERBB2-positive patients may be useful in personalized therapy trials, particularly in patients who are refractory to current treatment paradigms.

AB - Importance: ERBB2 (formerly HER2) is an important drug target in breast cancer, where anti-ERBB2 therapy has been shown to lead to improvements in disease recurrence and overall survival. ERBB2 status in head and neck squamous cell carcinoma (HNSCC) has not been well studied. Identification of ERBB2-positive tumors and characterization of response to ERBB2 therapy could lead to targeted treatment options in HNSCC. Objective: To identify ERBB2 aberrations in HNSCCs and investigate the potential for ERBB2-targeted therapy in HNSCCs. Design, Setting, and Participants: A retrospective case series of patients with laryngeal (42 tumor specimens) and oral cavity (94 tumor specimens) SCC enrolled in the University of Michigan Head and Neck Specialized Program of Research Excellence was conducted. Publicly available sequencing data (The Cancer Genome Atlas), as well as data from other studies, were reviewed to identify additional mutations and overexpression in ERBB2 in HNSCC. Established HNSCC cell lines were used for follow-up in vitro analysis. The study was conducted from October 1, 2014, to August 30, 2015. Interventions: With the use of targeted, amplicon-based sequencing with the Oncomine Cancer Panel, the copy number and mutation status of commonly altered genes in HNSCCs were assessed. Immunohistochemical staining was performed on tissue microarrays of HNSCCs to assess the expression of ERBB2. Western blotting for HNSCC cell line ERBB2 expression and cell survival assays after treatment with ERBB2 inhibitors were performed. Main Outcomes and Measures: The prevalence of ERBB2 genetic aberrations and ERBB2 overexpression in laryngeal and oral cavity SCCs, prevalence of ERBB2 aberrations in HNSCC in The Cancer Genome Atlas, ERBB2 protein expression in HNSCC cell lines, and response of HNSCC cell lines to targeted ERBB2 inhibitors. Results: Of the 42 laryngeal SCC samples screened by targeted sequencing, 4 (10%) were positive for ERBB2 amplification. Two of these samples showed ERBB2 overexpression on immunohistochemistry. Two of the 94 oral cavity SCC samples (2%) were positive for ERBB2 on immunohistochemistry. Analysis of 288 patients from publicly available HNSCC sequencing data revealed 9 amplifications (3%) in ERBB2. Protein expression was variable across HNSCC cell lines, and a subset of these cell lines showed responsiveness to anti-ERBB2 therapy. Conclusions and Relevance: ERBB2 aberrations were identified in a subset of HNSCCs. These tumors may be responsive to targeted therapy against ERBB2. Screening for ERBB2 aberrations and applying targeted therapy in ERBB2-positive patients may be useful in personalized therapy trials, particularly in patients who are refractory to current treatment paradigms.

UR - http://www.scopus.com/inward/record.url?scp=84974824038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974824038&partnerID=8YFLogxK

U2 - 10.1001/jamaoto.2016.0335

DO - 10.1001/jamaoto.2016.0335

M3 - Article

C2 - 27077364

AN - SCOPUS:84974824038

VL - 142

SP - 559

EP - 567

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 6

ER -